VN January 2021
Vetnuus | Januarie 2021 6 Antimicrobial resistance is a substantial threat to human health. Annually, around 700,000 humans die of drug-resistant microbial infections; this number could rise to 10 million by 2050 unless current antimicrobial druguse trends are reversed. 1 Bacterial resistance as a cause of therapeutic failure is less recognised in veterinary medicine because many clinicians in general practice do not have experience caring for patients with drug-resistant UTIs or drug-resistant skin or wound infections. Antimicrobial drugs are frequently prescribed for companion animals. A study surveying the records of dogs and cats over a 2-year period at a subset of clinics in the United Kingdom found that 25% of dogs and 21% of cats received antimicrobial treatment. 2 Of the antimicrobial drugs administered, 34% of those given to cats and 6% of those given to dogs were drugs determined by the World Health Organisation to be of critical importance to human health (ie, fluoroquinolones, macrolides, third-generation cephalosporins). 2,3 Methicillin-resistant Staphylococcus pseudintermedius can be resistant to all antimicrobial drugs used in veterinary medicine, and many other pathogenic organisms (eg, methicillin-resistant S aureus , extended-spectrum β-lactamase–producing Escherichia coli , carbapenemase-producing E coli and Klebsiella pneumoniae , multidrug-resistant enterococci) can colonise and infect both farm and companion animals. 4 Because pet owners and veterinary staff have close connections with companion animals, there is also an increased risk for organism transfer between species 5-7 ; young children and immunocompromised pet owners are at the greatest risk. Responsible antimicrobial stewardship reduces inappropriate antimicrobial use, 4 improves appropriate antimicrobial use, and reduces the risk for transfer of drug-resistant pathogens between humans and animals. How Does Bacterial Resistance Develop? Bacterial resistance did not start with the discovery of penicillin. Antimicrobial-resistance mechanisms developed in bacteria >2 billion years ago. 8 Antimicrobial drugs preferentially target resistant populations of bacteria. Selection and clonal amplification of resistant bacterial strains are more likely to occur at sites associated with lower and variable antimicrobial concentrations (i.e., sites other than the infection site) – either the gut and skinmicrobiome or the inanimate environment following excretion of the therapeutic agent or its metabolic breakdown products. 9 Resolution of infection following antimicrobial therapy does not indicate resistance has not occurred. 10 Resistance always occurs to some degree in the normal flora in the skin and gut but can also emerge at the site of infection if treatment was inadequate or inappropriate. 9 Themicrobiome is the collection of microorganisms living in or on a human or animal body. A healthy immune system is able to keep the microbiome in balance. 11 Understanding the impact antimicrobial use has on the microbiome is crucial to comprehending the effects of prescribing antimicrobial drugs inappropriately. Human and animal immune systems have developed the ability to cohabit with and control microbiota. 11 Dysbiosis occurs when control of these microbiota is lost. The structure of the microbial community can be influenced by various factors (e.g., host genetics, diet, infection, antimicrobial use). 12 Many antimicrobial drugs have long-lasting effects, which can lead to permanent loss of some organisms and proliferation and persistence of other bacteria. 12 A substantial increase in chronic inflammatory and autoimmune disorders in humans has been attributed, at least in part, to the use of antimicrobial drugs, changes in diet, and a reduction in intestinal parasitism. These changes have profoundly affected human microbiota and, as a direct result, the immune system and are believed to be a factor in a variety of diseases associated with abnormal immune responses toward environmental antigens and self-antigens (e.g., inflammatory bowel disease, multiple sclerosis, type 1 diabetes, allergies, asthma). 12,13 Responsible Antimicrobial Stewardship Jill Maddison, BVSc, DipVetClinStud, PhD, SFHEA, MRCVS, Royal Veterinary College, London, United Kingdom (First published in Clinician’s Brief, November 2019. Reprinted with permission) Leading Article
Made with FlippingBook
RkJQdWJsaXNoZXIy OTc5MDU=